Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2011 (2011), Article ID 841564, 9 pages
http://dx.doi.org/10.1155/2011/841564
Research Article

Effect of Supplementation of Tanshinone IIA and Sodium Tanshinone IIA Sulfonate on the Anticancer Effect of Epirubicin: An In Vitro Study

1Department of Surgical Medicine, Erlin Branch of Changhua Christian Hospital, Changhua 526, Taiwan
2Comprehensive Breast Cancer Center, Changhua Christian Hospital, Changhua 500, Taiwan
3Department and Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan
4School of Medicine, College of Health Care and Management, Chung Shan Medical University, Taichung 40201, Taiwan
5School of Nutrition, College of Health Care and Management, Chung Shan Medical University, Taichung 40201, Taiwan
6Department of Pharmacology, Changhua Christian Hospital, Changhua 500, Taiwan
7Department of Pharmacology, School of Pharmacology, China Medical University, Taichung 40402, Taiwan

Received 9 November 2010; Revised 6 January 2011; Accepted 7 March 2011

Copyright © 2011 Szu-Erh Chan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward et al., “Cancer statistics, 2006,” CA: A Cancer Journal for Clinicians, vol. 56, no. 2, pp. 106–130, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. Bureau of Health Promotion, Department of Health, Bureau of Health Promotion Annual Report 2008~2009, Bureau of Health Promotion, Department of Health, Taichung City, Taiwan, 2009.
  3. D. J. Booser and G. N. Hortobagyi, “Anthracycline antibiotics in cancer therapy. Focus on drug resistance,” Drugs, vol. 47, no. 2, pp. 223–258, 1994. View at Google Scholar · View at Scopus
  4. National Comprehensive Cancer Network (NCCN), “Breast cancer,” in NCCN Clinical Practice Guidelines in Oncology, NCCN, Ed., National Comprehensive Cancer Network, Fort Washington, Pa, USA, 2010. View at Google Scholar
  5. A. Goldhirsch, J. N. Ingle, R. D. Gelber, A. S. Coates, B. Thürlimann, and H. J. Senn, “Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009,” Annals of Oncology, vol. 20, no. 8, pp. 1319–1329, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. C. T. Stinis and M. R. Movahed, “Cardiac evaluation, toxicity and monitoring in the treatment of breast cancer,” Seminars in Breast Disease, vol. 9, no. 4, pp. 160–167, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Raschi, V. Vasina, M. G. Ursino, G. Boriani, A. Martoni, and F. De Ponti, “Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy,” Pharmacology and Therapeutics, vol. 125, no. 2, pp. 196–218, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Shan, A. M. Lincoff, and J. B. Young, “Anthracycline-induced cardiotoxicity,” Annals of Internal Medicine, vol. 125, no. 1, pp. 47–58, 1996. View at Google Scholar · View at Scopus
  9. J. Bonneterre, H. Roché, P. Kerbrat et al., “Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French Adjuvant Study Group,” Journal of Clinical Oncology, vol. 22, no. 15, pp. 3070–3079, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. M. T. Meinardi, W. T. Van Der Graaf, J. A. Gietema et al., “Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques,” Heart, vol. 88, no. 1, pp. 81–82, 2002. View at Google Scholar · View at Scopus
  11. M. Ryberg, D. Nielsen, T. Skovsgaard, J. Hansen, B. V. Jensen, and P. Dombernowsky, “Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer,” Journal of Clinical Oncology, vol. 16, no. 11, pp. 3502–3508, 1998. View at Google Scholar · View at Scopus
  12. M. Ryberg, D. Nielsen, G. Cortese, G. Nielsen, T. Skovsgaard, and P. K. Andersen, “New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients,” Journal of the National Cancer Institute, vol. 100, no. 15, pp. 1058–1067, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. T. O. Cheng, “Cardiovascular effects of Danshen,” International Journal of Cardiology, vol. 121, no. 1, pp. 9–22, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. M. H. Li, J. M. Chen, Y. Peng, Q. Wu, and P. G. Xiao, “Investigation of Danshen and related medicinal plants in China,” Journal of Ethnopharmacology, vol. 120, no. 3, pp. 419–426, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. H. M. Jin, “Clinical application of Salvia miltiorrhizae and the investigation of its mechanism for activating the blood circulation to eliminate blood stasis,” Chinese Journal of Natural Medicines, vol. 58, pp. 180–183, 1978. View at Google Scholar
  16. C. Z. Li, J. B. Lin, S. C. Yang, F. D. Zhao, and J. C. Zhang, “Effect of Salvia miltiorrhizae on the release of vasoconstrictive substance of platelets,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 4, p. 565, 1984. View at Google Scholar
  17. X. X. Zhu, “Effect of danshan and persantin on the alteration of platelet aggregation and microcirculation in diabetics,” Zhonghua Nei Ke Za Zhi, vol. 24, no. 4, pp. 197–199, 1985. View at Google Scholar · View at Scopus
  18. X. S. Ouyang, K. Takahashi, K. Komatsu et al., “Protective effect of Salvia miltiorrhiza on angiotensin II-induced hypertrophic responses in neonatal rat cardiac cells,” Japanese Journal of Pharmacology, vol. 87, no. 4, pp. 289–296, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Yang, X. Zou, Q. Liang et al., “Sodium tanshinone IIA sulfonate depresses angiotensin II-induced cardiomyocyte hypertrophy through MEK/ERK pathway,” Experimental and Molecular Medicine, vol. 39, no. 1, pp. 65–73, 2007. View at Google Scholar · View at Scopus
  20. G. Y. Zhou, B. L. Zhao, J. W. Hou, G. E. Ma, and W. J. Xin, “Protective effects of sodium tanshinone IIA sulphonate against adriamycin-induced lipid peroxidation in mice hearts in vivo and in vitro,” Pharmacological Research, vol. 40, no. 6, pp. 487–491, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. A. M. Wang, S. H. Sha, W. Lesniak, and J. Schacht, “Tanshinone (Salviae miltiorrhizae extract) preparations attenuate aminoglycoside-induced free radical formation in vitro and ototoxicity in vivo,” Antimicrobial Agents and Chemotherapy, vol. 47, no. 6, pp. 1836–1841, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. K. A. Wouters, L. C. M. Kremer, T. L. Miller, E. H. Herman, and S. E. Lipshultz, “Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies,” British Journal of Haematology, vol. 131, no. 5, pp. 561–578, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. W. A. He and Q. T. Zeng, “The protective effects of sodium tanshinone IIA sulfonate preconditioning on ischemia-reperfusion injury of heart in rats,” Chinese Journal of the Practical Chinese with Modern Medicine, vol. 18, pp. 1890–1892, 2005. View at Google Scholar
  24. J. Gao, G. Yang, R. Pi et al., “Tanshinone IIA protects neonatal rat cardiomyocytes from adriamycin-induced apoptosis,” Translational Research, vol. 151, no. 2, pp. 79–87, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Fu, H. Huang, J. Liu, R. Pi, J. Chen, and P. Liu, “Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis,” European Journal of Pharmacology, vol. 568, no. 1–3, pp. 213–221, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Jiang, L. Zhang, Y. Wang et al., “Tanshinone IIA sodium sulfonate protects against cardiotoxicity induced by doxorubicin in vitro and in vivo,” Food and Chemical Toxicology, vol. 47, no. 7, pp. 1538–1544, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Yang, A. Liu, X. Ma, L. Li, D. Su, and J. Liu, “Sodium tanshinone IIA sulfonate protects cardiomyocytes against oxidative stress-mediated apoptosis through inhibiting JNK activation,” Journal of Cardiovascular Pharmacology, vol. 51, no. 4, pp. 396–401, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. C. E. Delaney, S. P. Hopkins, and C. L. Addison, “Supplementation with l-carnitine does not reduce the efficacy of epirubicin treatment in breast cancer cells,” Cancer Letters, vol. 252, no. 2, pp. 195–207, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. P. M. Duffy, M. C. Hayes, A. Cooper, and C. J. Smart, “Determination and reversal of resistance to epirubicin intravesical chemotherapy. A flow cytometric model,” British Journal of Urology, vol. 77, no. 6, pp. 819–823, 1996. View at Google Scholar · View at Scopus
  30. T. C. Chou and P. Talalay, “A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems,” Journal of Biological Chemistry, vol. 252, no. 18, pp. 6438–6442, 1977. View at Google Scholar · View at Scopus
  31. T. C. Chou and P. Talalay, “Applications of the median effect principle for the assessment of low dose risk of carcinogenesis and for the quantitation of synergism and antagonism of chemotherapeutic agents,” in New Avenues in Development Cancer Chemotherapy, K. R. Harra and T. A. Connors, Eds., Bristol-Myers Symposium Series, pp. 37–64, Academic Press, New York, NY, USA, 1987. View at Google Scholar
  32. E. Tokunaga, Y. Kimura, K. Mashino et al., “Activation of PI3K/Akt signaling and hormone resistance in breast cancer,” Breast Cancer, vol. 13, no. 2, pp. 137–144, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Knuefermann, Y. Lu, B. Liu et al., “HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells,” Oncogene, vol. 22, no. 21, pp. 3205–3212, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. A. S. Clark, K. West, S. Streicher, and P. A. Dennis, “Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells,” Molecular Cancer Therapeutics, vol. 1, no. 9, pp. 707–717, 2002. View at Google Scholar · View at Scopus
  35. J. J. Liu, D. J. Lin, P. Q. Liu, M. Huang, X. D. Li, and R. W. Huang, “Induction of apoptosis and inhibition of cell adhesive and invasive effects by tanshinone IIA in acute promyelocytic leukemia cells in vitro,” Journal of Biomedical Science, vol. 13, no. 6, pp. 813–823, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Wang, X. Wang, S. Jiang et al., “Growth inhibition and induction of apoptosis and differentiation of tanshinone IIA in human glioma cells,” Journal of Neuro-Oncology, vol. 82, no. 1, pp. 11–21, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. X. Wang, Y. Wei, S. Yuan et al., “Potential anticancer activity of tanshinone IIA against human breast cancer,” International Journal of Cancer, vol. 116, no. 5, pp. 799–807, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. S. L. Yuan, Y. Q. Wei, X. J. Wang, F. Xiao, S. F. Li, and J. Zhang, “Growth inhibition and apoptosis induction of tanshinone II-A on human hepatocellular carcinoma cells,” World Journal of Gastroenterology, vol. 10, no. 14, pp. 2024–2028, 2004. View at Google Scholar · View at Scopus
  39. L. J. Yang, C. J. Jeng, H. N. Kung et al., “Tanshinone IIA isolated from Salvia miltiorrhiza elicits the cell death of human endothelial cells,” Journal of Biomedical Science, vol. 12, no. 2, pp. 347–361, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. R. S. Hotchkiss, A. Strasser, J. E. McDunn, and P. E. Swanson, “Cell death,” New England Journal of Medicine, vol. 361, no. 16, pp. 1570–1583, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. P. Limtrakul, W. Chearwae, S. Shukla, C. Phisalphong, and S. V. Ambudkar, “Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin,” Molecular and Cellular Biochemistry, vol. 296, no. 1-2, pp. 85–95, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. N. Aouali, L. Eddabra, J. Macadré, and H. Morjani, “Immunosuppressors and reversion of multidrug-resistance,” Critical Reviews in Oncology/Hematology, vol. 56, no. 1, pp. 61–70, 2005. View at Publisher · View at Google Scholar · View at Scopus